Pmv Pharmaceuticals Inc (PMVP)
$1.68
Live
Insights on Pmv Pharmaceuticals Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 111.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 335.8%
Performance
- $1.66$1.72$1.68
1.49%
Downside
Day's Volatility :3.78%
Upside
2.33%
- $1.18$9.72$1.68
29.76%
Downside
52 Weeks Volatility :87.86%
Upside
82.72%
Returns
| Period | Pmv Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -1.74% | 1.7% | 0.0% |
6 Months | 37.4% | 11.3% | 0.0% |
1 Year | -61.94% | 5.4% | 1.3% |
3 Years | -95.17% | 13.9% | -22.1% |
Highlights
Market Capitalization | 92.9M |
Book Value | $4.39 |
Earnings Per Share (EPS) | -1.44 |
Wall Street Target Price | 8.75 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -19.17% |
Return On Equity TTM | -29.24% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -78.9M |
Diluted Eps TTM | -1.44 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.38 |
EPS Estimate Next Year | -1.42 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.41 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 420.83%
Technicals Summary
Sell
Neutral
Buy
Pmv Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Pmv Pharmaceuticals Inc | -0.59% | 37.4% | -61.94% | -95.17% | -95.49% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Pmv Pharmaceuticals Inc | NA | NA | NA | -1.38 | -0.29 | -0.19 | NA | 4.39 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Pmv Pharmaceuticals Inc | Buy | $92.9M | -95.49% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Orbimed Advisors, LLC
12.59%JPMorgan Chase & Co
7.64%BlackRock Inc
6.28%ArrowMark Colorado Holdings, LLC (ArrowMark Partners)
5.28%Euclidean Capital LLC
5.11%Vanguard Group Inc
4.68%
Corporate Announcements
Pmv Pharmaceuticals Inc Earnings
Pmv Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
pmv pharmaceuticals, inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. its lead product candidate is pc14586, a small molecule that corrects and restores p53 function. the company also develops product candidates for p53 r273h hotspot mutation and other p53 hotspot mutations. pmv pharmaceuticals, inc. was formerly known as pj pharmaceuticals, inc. and changed to in july 2013. the company was founded in 2013 and is headquartered in cranbury, new jersey.
Organization | Pmv Pharmaceuticals Inc |
Employees | 63 |
CEO | Dr. David H. Mack Ph.D. |
Industry | Commercial Services |
